For investors only

All about the drug candidate arfolitixorin
and related information


“Isofol should help to extend life expectancy and improve quality of life for cancer patients”

Business Concept

Isofol is focusing on developing arfolitixorin with the goal of making the drug available worldwide, thereby improving the quality of life of cancer patients treated with 5-FU-based therapies.


Arfolitixorin in oncology

The company’s development of arfolitixorin is based on an ambition that the potential drug should be an alternative to current standard treatment to reduce the tumor burden, increase the quality of life and life expectancy of needy patients with advanced colorectal cancer without compromising safety. Isofol’s drug candidate arfolitixorin has shown in extensive preclinical and clinical studies the potential to improve the effect of the cancer drug 5-FU – today’s standard treatment for colon and rectal cancer. Arfolitixorin is the first and only direct-acting folate-based drug candidate that enhances the tumor-inhibiting effect of 5-FU without giving rise to more side effects. The company has initiated a step-by-step process to enable a cost-effective and risk-minimizing continued development of arfolitixorin with the goal of making the treatment available to patients all over the world.

Organisational strategy

Isofol operates as a virtual organization that brings together key competencies through collaborations to ensure the best possible access to the resources required to drive the development of arfolitixorin forward in a professional and cost-effective manner.

Last updated 05-26-2023

Scroll to Top